Novo Nordisk (NVO), Why Is Fresh Attention Building Now?
OpenAI’s acquisition of biotech software startup Orchestra Bio has pulled Novo Nordisk (NYSE:NVO) into the spotlight again, since the drugmaker already uses OpenAI’s Rosalind AI platform for parts of its life sciences work.
The recent OpenAI move comes at a tricky moment for Novo Nordisk’s investors. The stock’s share price has fallen about 19% over the past 90 days, the year-to-date share price return is down 25.44%, and the 1-year total shareholder return has declined 24.34%. This points to fading momentum and a market that is reassessing both growth potential and risk around the business despite interest in its AI partnerships.
Scan beyond Novo Nordisk and this OpenAI link-up by sizing up a curated list of 37 healthcare AI stocks that could also be repositioning around AI in drug discovery and clinical workflows.
Bulls see Novo Nordisk’s AI ties and steady revenue as underappreciated, while bears point to the sharp share price slide and softer net income. Which story does the current valuation actually support next?
Most Popular Narrative: 62% Undervalued
Against a last close of $39.06, the most followed valuation story on Simply Wall St puts Novo Nordisk’s fair value at $102.97 and frames the recent selloff as overdone based on its GLP-1 pipeline and cash generation.
The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments. The number of Americans on GLP-1 therapy is projected to rise from approximately 10 million in 2025 to over 25 million by 2030 with further growth fueled by expanding indications, including treatments for cardiovascular disease, chronic kidney disease, sleep apnea, and potentially Alzheimer's.
See why 68 investors see Novo Nordisk as 62% undervalued.
Result: Fair Value of $102.97 (UNDERVALUED)
Still, the Novo Nordisk bull case can fray quickly if oral GLP-1 approvals arrive later than hoped or if Fast Track projects encounter costly clinical setbacks.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
Mixed signals like these around Novo Nordisk rarely last long, so consider both sides of the story promptly and form your own view with the full 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond Novo Nordisk?
If Novo Nordisk has your attention, do not stop there. Broaden your watchlist so you are not relying on a single story to shape your returns.
- Target potential mispricings by scanning a curated set of 33 high quality undervalued stocks that pair strong fundamentals with more modest expectations.
- Build a steadier income stream by reviewing 7 dividend fortresses that combine higher yields with an emphasis on resilience.
- Prioritise resilience first by focusing on a 31 resilient stocks with low risk scores that aims to limit unpleasant surprises when conditions change.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com